Comparing Canadian and United States opioid agonist therapy policies
Saved in:
Priest, K., et al., Comparing Canadian and United States opioid agonist therapy policies. International Journal of Drug Policy, vol. 74, 2019, 257-265 p.
Ref.
583079
Location:
SIIS R.1114 / SIIS Archivo (R.1114)
Palabras clave:
Drogodependencias, Drogas, Sobredosis, Opiáceos, Terapia, Tratamiento, Metadona, Buprenorfina, Políticas públicas, Control, Cobertura, Evaluación de servicios, Literatura científica, EE.UU., Canadá
Drogodependencias, Drogas, Sobredosis, Opiáceos, Terapia, Tratamiento, Metadona, Buprenorfina, Políticas públicas, Control, Cobertura, Evaluación de servicios, Literatura científica, EE.UU., Canadá
Similar Items: Comparing Canadian and United States opioid agonist therapy policies
- Interim opioid agonist treatment for opioid addiction: a systematic review
- Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services
- FROM MORPHINE CLINICS TO BUPRENORPHINE: REGULATING OPIOID AGONIST TREATMENT OF ADDICTION IN THE UNITED STATES
- Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study
- The impact of cocaine use in patients enrolled in opioid agonist therapy in Ontario, Canada
- VARIATIONS IN EVIDENCE-BASED CLINICAL PRACTICES IN NINE UNITED STATES VETERANS ADMINISTRATION OPIOID AGONIST THERAPY CLINICS